Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ovid Therapeutics ( (OVID) ) has provided an update.
On July 9, 2025, Ovid Therapeutics held its annual stockholders meeting, where several key proposals were voted on. Stockholders elected directors for a three-year term, approved executive compensation, ratified KPMG LLP as the accounting firm, and authorized a potential reverse stock split, indicating strategic financial adjustments.
The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
Ovid Therapeutics’ stock score is primarily impacted by its financial instability, with inconsistent revenue and ongoing losses overshadowing positive technical indicators. The valuation score is low due to negative earnings and lack of dividends. Technical analysis suggests potential short-term gains, but financial challenges present significant long-term risks.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing therapies for rare neurological conditions.
Average Trading Volume: 926,905
Technical Sentiment Signal: Sell
Current Market Cap: $30.58M
Find detailed analytics on OVID stock on TipRanks’ Stock Analysis page.